

Biotechnology Fund
SCHEDULE OF INVESTMENTS (Unaudited)

June 30, 2017

	Shares	Value
COMMON STOCKS[†] - 99.5%		
Biotechnology - 63.1%		
Amgen, Inc.	114,999	\$ 19,806,277
Celgene Corp.*	139,479	18,114,138
Gilead Sciences, Inc.	251,265	17,784,537
Biogen, Inc.*	50,275	13,642,624
Regeneron Pharmaceuticals, Inc.*	26,112	12,824,648
Vertex Pharmaceuticals, Inc.*	78,287	10,088,846
Incyte Corp.*	76,217	9,596,482
Illumina, Inc.*	51,897	9,005,167
Alexion Pharmaceuticals, Inc.*	70,462	8,573,112
BioMarin Pharmaceutical, Inc.*	76,762	6,971,525
Exelixis, Inc.*	213,370	5,255,303
Bio-Rad Laboratories, Inc. — Class A*	20,582	4,657,912
Bioerativ, Inc.*	77,047	4,635,918
Alnylam Pharmaceuticals, Inc.*	57,041	4,549,590
Seattle Genetics, Inc.*	83,327	4,311,339
Kite Pharma, Inc.* ¹	40,900	4,240,103
Ionis Pharmaceuticals, Inc.*	83,341	4,239,557
United Therapeutics Corp.*	31,446	4,079,490
Charles River Laboratories International, Inc.*	39,018	3,946,671
Exact Sciences Corp.* ¹	104,844	3,708,332
Juno Therapeutics, Inc.* ¹	123,345	3,686,782
Puma Biotechnology, Inc.*	38,110	3,330,814
Intrexon Corp.* ¹	125,520	3,023,777
Bluebird Bio, Inc.*	28,780	3,023,339
Intercept Pharmaceuticals, Inc.* ¹	24,760	2,997,693
Medicines Co.* ¹	77,908	2,961,283
Ligand Pharmaceuticals, Inc. — Class B*	23,477	2,850,108
Sage Therapeutics, Inc.*	35,720	2,844,741
Ultragenyx Pharmaceutical, Inc.*	43,010	2,671,351
Spark Therapeutics, Inc.*	40,220	2,402,743
Prothena Corporation plc ¹	43,833	2,372,242
Myriad Genetics, Inc.*	88,637	2,290,380
Halozyme Therapeutics, Inc.*	177,225	2,272,025
Esperion Therapeutics, Inc.* ¹	43,300	2,003,924
Accelaron Pharma, Inc.*	60,880	1,850,143
Five Prime Therapeutics, Inc.*	56,530	1,702,118
Acorda Therapeutics, Inc.*	84,166	1,658,070
AMAG Pharmaceuticals, Inc.*	86,926	1,599,438
Alder Biopharmaceuticals, Inc.* ¹	90,400	1,035,080
Total Biotechnology		216,607,622
Pharmaceuticals - 30.0%		
AbbVie, Inc.	257,534	18,673,790
Shire plc ADR	79,040	13,062,941
TESARO, Inc.*	34,213	4,785,030
Clovis Oncology, Inc.*	45,500	4,260,165
Portola Pharmaceuticals, Inc.*	71,635	4,023,738
PRA Health Sciences, Inc.*	52,030	3,902,770
Jazz Pharmaceuticals plc*	24,920	3,875,060
Neurocrine Biosciences, Inc.* ¹	81,721	3,759,166
Akorn, Inc.*	107,793	3,615,377
Alkermes plc*	60,578	3,511,707
ACADIA Pharmaceuticals, Inc.*	119,374	3,329,341
Nektar Therapeutics*	168,397	3,292,161
Ironwood Pharmaceuticals, Inc. — Class A*	165,626	3,127,019
Avexis, Inc.* ¹	36,500	2,998,840
Agios Pharmaceuticals, Inc.*	52,904	2,721,911
Horizon Pharma plc*	222,814	2,644,802
Pacira Pharmaceuticals, Inc.*	54,740	2,611,098
Radius Health, Inc.* ¹	53,570	2,422,971
Sarepta Therapeutics, Inc.*	69,350	2,337,789
Array BioPharma, Inc.* ¹	269,750	2,257,808
Impax Laboratories, Inc.*	134,690	2,168,509
Amicus Therapeutics, Inc.*	211,110	2,125,878
Eagle Pharmaceuticals, Inc.* ¹	25,860	2,040,095
Synergy Pharmaceuticals, Inc.* ¹	378,700	1,685,215
Depomed, Inc.*	142,014	1,525,230
Heron Therapeutics, Inc.* ¹	107,650	1,490,953
Global Blood Therapeutics, Inc.*	36,100	987,335
Total Pharmaceuticals		103,236,699
Healthcare-Products - 3.2%		
Bio-Techne Corp.	32,652	3,836,610
OPKO Health, Inc.* ¹	515,439	3,391,589
QIAGEN N.V.*	76,906	2,578,658
MiMedx Group, Inc.* ¹	73,100	1,094,307
Total Healthcare-Products		10,901,164
Healthcare-Services - 2.3%		
Quintiles IMS Holdings, Inc.*	87,944	7,870,988
Commercial Services - 0.9%		
Incorporated Research Holdings, Inc. — Class A* ¹	52,010	3,042,585
Total Common Stocks (Cost \$204,700,079)		341,659,058
RIGHTS^{†††} - 0.0%		
Chelsea Therapeutics International		
Expires 12/31/17*	231,107	—
Dyax Corp.		
Expires 01/25/18*	167,165	—
Clinical Data, Inc.		
Expires 12/31/20*	24,000	—
Total Rights (Cost \$17,304)		—
	Face	
	Amount	
REPURCHASE AGREEMENTS^{††2} - 0.2%		
RBC Capital Markets LLC issued 06/30/17 at 1.01% due 07/03/17	\$ 401,517	401,517
Bank of America Merrill Lynch issued 06/30/17 at 1.08% due 07/03/17	148,684	148,684
Total Repurchase Agreements (Cost \$550,201)		550,201
	Shares	
SECURITIES LENDING COLLATERAL^{†3} - 7.3%		
First American Government Obligations Fund — Class Z, 0.84% ⁴	25,210,936	25,210,936
Total Securities Lending Collateral (Cost \$25,210,936)		25,210,936
Total Investments - 107.0% (Cost \$230,478,520)		
	\$	367,420,195
Other Assets & Liabilities, net - (7.0)%		(23,890,861)
Total Net Assets - 100.0%	\$	343,529,334

-
- * *Non-income producing security.*
 - † *Value determined based on Level 1 inputs.*
 - †† *Value determined based on Level 2 inputs.*
 - ††† *Value determined based on Level 3 inputs.*
 - ¹ *All or portion of this security is on loan at June 30, 2017.*
 - ² *Repurchase Agreements.*
 - ³ *Securities lending collateral.*
 - ⁴ *Rate indicated is the 7 day yield as of June 30, 2017.*
- ADR — American Depositary Receipt
plc — Public Limited Company
-